Solubility of α-synuclein species in the L62 mouse model of synucleinopathy.
Alpha-synuclein
Mouse model
Parkinson’s disease
Protein aggregation
Protein solubility
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 03 2024
14 03 2024
Historique:
received:
04
11
2023
accepted:
11
03
2024
medline:
18
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
epublish
Résumé
The accumulation of α-synuclein (α-Syn) into Lewy bodies is a hallmark of synucleinopathies, a group of neurological disorders that include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Small oligomers as well as larger fibrils of α-Syn have been suggested to induce cell toxicity leading to a degenerative loss of neurones. A richer understanding of α-Syn aggregation in disease, however, requires the identification of the different α-Syn species and the characterisation of their biochemical properties. We here aimed at a more in-depth characterisation of the α-Syn transgenic mice, Line 62 (L62), and examined the deposition pattern and solubility of human and murine α-Syn in these mice using immunohistochemical and biochemical methods. Application of multiple antibodies confirmed mAb syn204 as the most discriminatory antibody for human α-Syn in L62. Syn204 revealed an intense and widespread immunohistochemical α-Syn labelling in parietal cortex and hippocampus, and to a lower level in basal forebrain and hindbrain regions. The labelled α-Syn represented somatic inclusions as well as processes and synaptic endings. Biochemical analysis revealed a Triton-resistant human α-Syn pool of large oligomers, a second pool of small oligomers that was not resistant to solubilization with urea/Triton. A third SDS-soluble pool of intermediate sized aggregates containing a mixture of both, human and mouse α-Syn was also present. These data suggest that several pools of α-Syn can exist in neurones, most likely in different cellular compartments. Information about these different pools is important for the development of novel disease modifying therapies aimed at α-Syn.
Identifiants
pubmed: 38486089
doi: 10.1038/s41598-024-56735-6
pii: 10.1038/s41598-024-56735-6
pmc: PMC10940722
doi:
Substances chimiques
alpha-Synuclein
0
Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6239Subventions
Organisme : TauRx Pharmaceuticals
ID : PAR1577
Informations de copyright
© 2024. The Author(s).
Références
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8968-73
pubmed: 12084935
Exp Neurol. 2002 May;175(1):35-48
pubmed: 12009758
Front Neurosci. 2018 Feb 19;12:80
pubmed: 29515354
Front Mol Neurosci. 2018 Jan 10;10:447
pubmed: 29375308
Science. 2000 Feb 18;287(5456):1265-9
pubmed: 10678833
Mol Cell Neurosci. 2003 Oct;24(2):419-29
pubmed: 14572463
Ann N Y Acad Sci. 2000;920:16-27
pubmed: 11193145
J Neurosci Res. 2002 Jun 1;68(5):568-78
pubmed: 12111846
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11113-11115
pubmed: 31110017
Neurobiol Aging. 2003 Mar-Apr;24(2):245-58
pubmed: 12498958
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11282-6
pubmed: 8248242
Neurobiol Aging. 2021 May;101:207-220
pubmed: 33639338
Am J Pathol. 1998 Apr;152(4):879-84
pubmed: 9546347
Nat Genet. 1998 Mar;18(3):231-6
pubmed: 9500544
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
Neurobiol Dis. 2001 Jun;8(3):535-9
pubmed: 11442360
Nat Rev Neurosci. 2013 Jan;14(1):38-48
pubmed: 23254192
Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
Trends Cell Biol. 2017 Jul;27(7):468-479
pubmed: 28259601
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73
pubmed: 9600990
J Neurosci. 2000 Aug 15;20(16):6021-9
pubmed: 10934251
Mol Psychiatry. 2022 Jan;27(1):758-770
pubmed: 34561613
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Neuron. 2002 May 16;34(4):521-33
pubmed: 12062037
Front Neurosci. 2019 Jan 28;13:28
pubmed: 30745863
Behav Brain Res. 2018 Feb 26;339:153-168
pubmed: 29180135
Acta Neuropathol. 2022 Apr;143(4):453-469
pubmed: 35141810
Science. 2010 Sep 24;329(5999):1663-7
pubmed: 20798282
Cell Mol Life Sci. 2015 Jun;72(11):2199-222
pubmed: 25523019
ACS Chem Neurosci. 2019 Apr 17;10(4):1915-1922
pubmed: 30253092
Neuron. 2003 Feb 20;37(4):583-95
pubmed: 12597857
Mol Neurodegener. 2019 Jul 22;14(1):29
pubmed: 31331359
J Biol Chem. 2001 Jan 26;276(4):2380-6
pubmed: 11060312
Anat Sci Int. 2019 Jan;94(1):11-22
pubmed: 30362073
Cell Signal. 2022 Sep;97:110386
pubmed: 35709886
Acta Neuropathol. 2020 Jun;139(6):977-1000
pubmed: 32356200